Inventor · disambiguated record
Camille Bedrosian
Also filed as: BEDROSIAN CAMILLE · BEDROSIAN CAMILLE L
9 granted patents·19 pending applications·170 citations·filing 1998–2025
88Inventor score
Files withALEXION PHARMA INC15BEDROSIAN CAMILLE L2INST GENETICS LLC2ARIAD GENE THERAPEUTICS INC1CLACKSON TIMOTHY P1
Top patents by PatentIndex Score
28 records- 0194US9447176B2Methods and compositions for treating complement-associated disordersROTHER RUSSELL P·Filed 2009·Granted Sep 20, 2016·21 cites·4 claims
- 0293US9771418B2Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Granted Sep 26, 2017·8 cites·4 claims
- 0390US6540993B1Method of treating inflammatory bowel disease using a topical formulation of IL-11INST GENETICS LLC·Filed 2000·Granted Apr 1, 2003·44 cites·12 claims
- 0486US6126933AMethods of treating inflammatory bowel diseases by administering IL-11GENETICS INST·Filed 1998·Granted Oct 3, 2000·90 cites·19 claims
- 0580US12459992B2Methods for treatment of refractory generalized myasthenia gravisALEXION PHARMA INC·Filed 2021·Granted Nov 4, 2025·1 cites·15 claims
- 0674US6887461B1Method of using IL-11 for treating mucositisINST GENETICS LLC·Filed 2000·Granted May 3, 2005·5 cites·28 claims
- 0770US2020140531A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2019·Application pending·0 cites
- 0867US11459382B2Dosage and administration of anti-C5 antibodies for treatment of protein-losing enteropathy in patientsALEXION PHARMA INC·Filed 2018·Granted Oct 4, 2022·1 cites·17 claims
- 0965US2017369562A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2017·Application pending·0 cites
- 1062US2025154234A1Methods for treatment of refractory generalized myasthenia gravisALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 1162US2017015740A1Methods for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 1261US2016319004A1Methods and compositions for treating complement-associated disordersALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 1356US11244744B2Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitorALEXION PHARMA INC·Filed 2017·Granted Feb 8, 2022·0 cites·11 claims
- 1454US2005129658A1Topical formulation for delivery of interleukin-11Filed 2005·Application pending·0 cites
- 1553US11031102B2Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitorALEXION PHARMA INC·Filed 2015·Granted Jun 8, 2021·0 cites·7 claims
- 1652US2006194829A1Therapeutic materials and methodsCLACKSON TIMOTHY P·Filed 2005·Application pending·0 cites
- 1751US2009215812A1Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitorARIAD GENE THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 1850US2008081053A1Treatment MethodBEDROSIAN CAMILLE L·Filed 2005·Application pending·0 cites
- 1947US2020123238A1Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplantALEXION PHARMA INC·Filed 2018·Application pending·0 cites
- 2047US2003147849A1Topical formulations for delivery of interleukin-11WYETH CORP·Filed 2003·Application pending·0 cites
- 2145US2008207644A1Therapeutic materials and methodsSONIS STEPHEN T·Filed 2007·Application pending·0 cites
- 2245US2017342139A1Methods for Treatment of Refractory Generalized Myasthenia GravisALEXION PHARMA INC·Filed 2017·Application pending·0 cites
- 2344US2010266590A1Combination therapyDEMETRI GEORGE D·Filed 2007·Application pending·0 cites
- 2443US2007185150A1Therapeutic methodsBEDROSIAN CAMILLE L·Filed 2006·Application pending·0 cites
- 2543US2009311249A1Capecitabine Combination TherapyGIANNI LUCA·Filed 2007·Application pending·0 cites
- 2637US2018142010A1Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variantALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 2736US2019135903A1Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patientsALEXION PHARMA INC·Filed 2016·Application pending·0 cites
- 2836US2016168237A1Method for treating a complement mediated disorder caused by an infectious agent in a patientALEXION PHARMA INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Camille Bedrosian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →